Markets:

Overview

News

Currencies

International

Treasuries

Awakn Life Sciences Corp (OP:AWKNF)

0.0650 UNCHANGED

Last Price Updated: 3:11 PM EST, Dec 13, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations ↗

June 23, 2025

Via Stocktwits

Topics Cannabis

Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy ↗

October 15, 2024

Awakn Life Sciences partners with the University of Nottingham to advance in vivo testing of its aminoindane therapy for PTSD, with results expected by late 2024.

Via Benzinga

Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M ↗

September 18, 2024

Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate research into addiction treatments.

Via Benzinga

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗

April 17, 2024

Via Benzinga

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More ↗

February 15, 2024

Via Benzinga

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation ↗

December 21, 2023

Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has enter

Via Benzinga

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center ↗

November 15, 2023

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life...

Via Benzinga

U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy ↗

October 15, 2023

Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharmacologist by ScholarGPS, a California-based American company owned and...

Via Benzinga

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial ↗

September 06, 2023

Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III...

Via Benzinga

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics ↗

August 01, 2023

As part of its business restructuring process and following its London clinics busin

Via Benzinga

Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder ↗

July 26, 2023

On this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviews Awakn Life Sciences Corp. (OTC: AWKNF) CEO Anthony Tennyson, as his company moves closer towards a Phase III clinical...

Via Benzinga

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗

July 11, 2023

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...

Via Benzinga

Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next ↗

July 05, 2023

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic.

Via Benzinga

Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement ↗

June 15, 2023

UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the closing of the second tranche of its latest non-brokered private placement as well as an upsizing of the original...

Via Benzinga

Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism ↗

June 12, 2023

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of...

Via Benzinga

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗

May 01, 2023

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

Via Benzinga

Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion ↗

April 28, 2023

The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.

Via Benzinga

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study ↗

April 19, 2023

The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming

Via Benzinga

EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps ↗

April 19, 2023

In the current psychedelics landscape, one of the most important topics is compound legality. While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what...

Via Benzinga

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More ↗

April 17, 2023

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules

Via Benzinga

Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership ↗

April 14, 2023

Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate...

Via Benzinga

EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility ↗

March 19, 2023

In light of the latest news regarding the DEA’s telehealth regulations and the

Via Benzinga

Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event ↗

March 13, 2023

The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.